WallStSmart

Brainsway Ltd (BWAY)vsEdwards Lifesciences Corp (EW)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 10897% more annual revenue ($6.67B vs $60.70M). BWAY leads profitability with a 15.6% profit margin vs 15.3%. BWAY trades at a lower P/E of 42.1x. EW earns a higher WallStSmart Score of 54/100 (C-).

BWAY

Buy

51

out of 100

Grade: C-

Growth: 10.0Profit: 6.5Value: 4.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.40

EW

Buy

54

out of 100

Grade: C-

Growth: 5.3Profit: 8.0Value: 5.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BWAY.

EWUndervalued (+69.2%)

Margin of Safety

+69.2%

Fair Value

$257.48

Current Price

$107.15

$150.33 discount

UndervaluedFair: $257.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BWAY3 strengths · Avg: 10.0/10
Revenue GrowthGrowth
35.4%10/10

Revenue surging 35.4% year-over-year

EPS GrowthGrowth
59.8%10/10

Earnings expanding 59.8% YoY

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

EW4 strengths · Avg: 9.8/10
Operating MarginProfitability
30.1%10/10

Strong operational efficiency at 30.1%

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Market CapQuality
$59.81B9/10

Large-cap with strong market position

Areas to Watch

BWAY3 concerns · Avg: 2.3/10
Market CapQuality
$406.96M3/10

Smaller company, higher risk/reward

P/E RatioValuation
42.1x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.402/10

Distress zone — elevated risk

EW3 concerns · Avg: 3.0/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
60.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : BWAY

The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 12.5%. Revenue growth of 35.4% demonstrates continued momentum.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 30.1%. Revenue growth of 10.5% demonstrates continued momentum.

Bear Case : BWAY

The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 42.1x leaves little room for execution misses.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 60.5x leaves little room for execution misses.

Key Dynamics to Monitor

BWAY profiles as a growth stock while EW is a mature play — different risk/reward profiles.

EW carries more volatility with a beta of 0.83 — expect wider price swings.

BWAY is growing revenue faster at 35.4% — sustainability is the question.

EW generates stronger free cash flow (507M), providing more financial flexibility.

Bottom Line

EW scores higher overall (54/100 vs 51/100), backed by strong 15.3% margins and 10.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Brainsway Ltd

HEALTHCARE · MEDICAL DEVICES · USA

Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?